{"id":464120,"date":"2010-03-23T17:22:00","date_gmt":"2010-03-23T21:22:00","guid":{"rendered":"tag:typepad.com,2003:post-6a00d8341c89dd53ef0120a9640289970b"},"modified":"2010-03-25T10:57:18","modified_gmt":"2010-03-25T14:57:18","slug":"antibiotic-avelox-linked-to-severe-liver-injury-side-effects-again","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/464120","title":{"rendered":"Antibiotic Avelox Linked To Severe Liver Injury Side Effects, Again"},"content":{"rendered":"<div xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<p><strong><span style=\"FONT-SIZE: 14px\"><span style=\"FONT-SIZE: 15px\"><span style=\"FONT-SIZE: 16px\">Will The FDA Be The\u00a0Last To Insist On Increased Warning; In Fall 2007 Bayer Updated\u00a0Its Avalox Label In Europe<\/span><\/span><\/span><\/strong><\/p>\n<p><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><font size=\"2\"><strong>(Posted by Tom Lamb at <a href=\"http:\/\/www.drug-injury.com\/\" ><span style=\"COLOR: #003366\"><font size=\"2\"><strong>DrugInjuryWatch.com<\/strong><\/font><\/span><\/a><font size=\"2\"><strong>)<\/strong><\/font><\/strong><\/font><\/span><\/span><\/span><\/span><\/span><\/p>\n<p>On March 22, 2010 Health Canada issued a press release, <a href=\"http:\/\/www.hc-sc.gc.ca\/ahc-asc\/media\/advisories-avis\/_2010\/2010_42-eng.php#pmfa\" >&#8220;Updated Labelling for Antibiotic Avelox (Moxifloxacin) Regarding Rare Risk of Severe Liver Injury Information Update&#8221;<\/a>, which informed doctors and patients about newly updated labeling information for\u00a0Avelox\u00a0in Canada\u00a0that incorporates important safety information related to the rare risk of severe liver problems when using Avelox.<\/p>\n<p>Symptoms of liver problems include:<\/p>\n<ul>\n<li>Abdominal pain;\n<li>Loss of appetite;\n<li>Yellowing of the skin and eyes;\n<li>Severe itching;\n<li>Dark urine; and,\n<li>Pale-colored stools. <\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/li>\n<\/ul>\n<p>In\u00a0its March 2010 press release about Avelox, Health Canada advised:\u00a0 <\/p>\n<blockquote dir=\"ltr\">\n<p>Patients who experience any of these symptoms are advised to stop taking Avelox and contact a health care professional immediately.<\/p>\n<\/blockquote>\n<p dir=\"ltr\">While this\u00a0advisory from Health Canada about Avelox is important, it is far from new.<\/p>\n<p>In an article which\u00a0we posted to this site more than two years ago, <a href=\"http:\/\/www.drug-injury.com\/druginjurycom\/2008\/02\/avelox-bayer-wa.html\" >&#8220;February 2008 &#8216;Dear Doctor&#8217; Letter About Avelox \/ Avalox Is Sent By Bayer In Europe&#8221;<\/a>,\u00a0we\u00a0reported that this letter from Bayer to doctors in Europe was intended to emphasize the addition of a warning about severe, possibly fatal liver injury to the package insert, or label, for Avalox (slightly different brand name for this antibiotic is used in the European Union) back in the fall of 2007.<\/p>\n<p>We\u00a0concluded\u00a0our February 2008 article about this Avalox &#8220;Dear Doctor&#8221; letter that Bayer sent out only in Europe with this remark:<\/p>\n<blockquote dir=\"ltr\">\n<p>We will watch for any similar Avelox &#8220;Dear Doctor&#8221; letter from Bayer here in the U.S.<\/p>\n<\/blockquote>\n<p>Two years later, we are still waiting and watching, here.<\/p>\n<p>It is unclear thus far whether Bayer will notify doctors in Canada by letter about the Avelox label change concerning the risk of liver injury for patients using this apparently unsafe antibiotic.<\/p>\n<p>Here&#8217;s\u00a0our\u00a0&#8220;obvious&#8221;\u00a0question to the FDA, now:\u00a0 Is the FDA looking at Avelox for serious side effects such as drug-induced hepatitis and liver failure, which seem to be unique to this antibiotic among the fluoroquinolones?<\/p>\n<p>We would like to hear about what you know regarding this liver-related Avelox safety issue.\u00a0 As always, please share by leaving a Comment, below.<\/p>\n<p>______________________________________________________________________________<\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/\" ><strong><span style=\"FONT-SIZE: 14px\"><font color=\"#810081\">DrugInjuryLaw.com<\/font><\/span><\/strong><\/a>: <span style=\"COLOR: #ff0000\"><span style=\"COLOR: #80c0ff\"><span style=\"COLOR: #800000\"><span style=\"COLOR: #302449\"><strong>Legal Information And News About Prescription Drug Side Effects<\/strong><\/span><\/span><\/span><\/span><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2010%2F03%2Ffda-zocor-simvastatin-vytorin-ezetimibe-zetia-simcor-niacin-myopathy-rhabdomyolysis-rhabdo.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2010\/03\/fda-zocor-simvastatin-vytorin-ezetimibe-zetia-simcor-niacin-myopathy-rhabdomyolysis-rhabdo.html&amp;showad=true\" type=\"text\/javascript\"><\/script><\/div>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=SmOZdCTHsRk:cNWDpogkt-U:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=SmOZdCTHsRk:cNWDpogkt-U:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=SmOZdCTHsRk:cNWDpogkt-U:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=SmOZdCTHsRk:cNWDpogkt-U:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=SmOZdCTHsRk:cNWDpogkt-U:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=SmOZdCTHsRk:cNWDpogkt-U:l6gmwiTKsz0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=l6gmwiTKsz0\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=SmOZdCTHsRk:cNWDpogkt-U:gIN9vFwOqvQ\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=SmOZdCTHsRk:cNWDpogkt-U:gIN9vFwOqvQ\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/drug-injury-watch\/~4\/SmOZdCTHsRk\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Will The FDA Be The\u00a0Last To Insist On Increased Warning; In Fall 2007 Bayer Updated\u00a0Its Avalox Label In Europe (Posted by Tom Lamb at DrugInjuryWatch.com) On March 22, 2010 Health Canada issued a press release, &#8220;Updated Labelling for Antibiotic Avelox (Moxifloxacin) Regarding Rare Risk of Severe Liver Injury Information Update&#8221;, which informed doctors and patients [&hellip;]<\/p>\n","protected":false},"author":2827,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-464120","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/464120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2827"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=464120"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/464120\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=464120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=464120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=464120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}